Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Pathology

Behind the Diagnosis: The Biology and Pathology of DFSP

At a Glance

Most cases of Dermatofibrosarcoma protuberans (DFSP) are driven by a specific genetic fusion called COL1A1-PDGFB. To confirm the diagnosis, pathologists look for a strong positive result for the CD34 cellular marker and check for aggressive features like fibrosarcomatous transformation (FS-DFSP).

The diagnosis of Dermatofibrosarcoma protuberans (DFSP) is confirmed by looking at the specific genetic and cellular features of the tumor. While it may look like a simple lump on the surface, its biology is driven by a very specific “glitch” in your DNA [1][2].

The Genetic Driver: A “Switched-On” Growth Signal

Most cases of DFSP (about 90%) are caused by a genetic event called a translocation [1][2]. This happens when two pieces of different chromosomes—specifically chromosome 17 and chromosome 22—break off and swap places [1][3].

This swap fuses two genes together: COL1A1 and PDGFB [1][2].

  • COL1A1 is a gene that is normally very active, as it helps build collagen.
  • PDGFB is a gene that tells cells to grow.

When they fuse, the “always-on” switch of the collagen gene is connected to the growth signal [4][5]. This results in the body overproducing a protein that keeps the tumor cells constantly dividing and growing [3][5]. Understanding this “glitch” is important because a targeted medicine called Imatinib works by specifically blocking this growth signal [6][7].

Cellular Markers: The Pathologist’s “Fingerprints”

To diagnose DFSP, pathologists use special stains called immunohistochemistry to identify unique proteins on the surface of the tumor cells [8][9].

  • CD34: This is the most critical marker for DFSP. In a classic case, almost all the tumor cells will “stain” strongly and evenly for CD34 [8][10].
  • Differentiating from Mimics: This staining helps doctors tell the difference between DFSP and harmless lumps. For example, a Dermatofibroma (a benign bump) usually shows very little CD34 and instead stains for a protein called Factor XIIIa [8][11]. Similarly, a Solitary Fibrous Tumor will show a protein called STAT6, which is not found in DFSP [12].

Your Pathology Report Checklist

Your pathology report is the “blueprint” of your cancer. When you review it with your doctor, ensure the following critical pieces of information are included:

Feature Why It Matters
Histologic Pattern Usually described as “spindle cells” in a “storiform” (wagon-wheel) pattern [8].
CD34 Status Confirms the tumor’s identity [8].
Margin Status Indicates if the tumor was completely removed or if “tentacles” remain at the edges [13][14].
Fibrosarcomatous Transformation This is a check for a more aggressive subtype (FS-DFSP) that requires closer monitoring [15][16].
Molecular Testing Use of FISH (Fluorescence In Situ Hybridization) or NGS to confirm the t(17;22) translocation, especially in complex cases [1][17].

If any of these items are missing or unclear, you can ask your doctor for a “second opinion” review by a specialist sarcoma pathologist to ensure the most accurate diagnosis [8].

Common questions in this guide

What does a CD34 positive result mean for DFSP?
CD34 is a specific protein found on the surface of cells. In dermatofibrosarcoma protuberans, almost all tumor cells typically stain strongly and evenly for CD34, which is the most critical marker pathologists use to confirm the diagnosis and distinguish it from harmless skin bumps.
What is the COL1A1-PDGFB gene fusion?
This is a genetic glitch found in about 90% of DFSP cases where parts of chromosome 17 and chromosome 22 swap places. This fuses a collagen-building gene with a cell-growth gene, acting as an 'always-on' switch that tells the tumor cells to continuously grow and divide.
What is fibrosarcomatous transformation (FS-DFSP)?
Fibrosarcomatous transformation indicates that the tumor has developed features of a more aggressive subtype, known as FS-DFSP. Finding this on your pathology report is important because this subtype requires closer monitoring by your medical team.
Why is margin status important on my pathology report?
Margin status indicates whether the tumor was completely removed during surgery. Clear margins mean no tumor cells were found at the edges of the removed tissue, while positive margins suggest that microscopic 'tentacles' of the tumor may still remain.
How does targeted therapy like Imatinib work for DFSP?
DFSP tumors are typically driven by a genetic mutation that causes the body to overproduce a continuous cell growth signal. Imatinib is a targeted therapy drug that works by specifically blocking this abnormal growth signal, helping to control the tumor.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my pathology report show 'classic' DFSP or 'fibrosarcomatous' (FS-DFSP) transformation?
  2. 2.How close was the tumor to the surgical margins, and what was the distance in millimeters?
  3. 3.If my tumor is CD34-negative, what other tests (like FISH or NGS) were used to confirm the diagnosis?
  4. 4.What was the 'mitotic rate' of my tumor, and how does that affect my prognosis?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    [Perianal dermatofibrosarcoma protuberans: a case report, review and update].

    Velasco Albendea FJ, Doña Girón J, Blanco Villar ML, et al.

    Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia 2019; (52(1)):62-68 doi:10.1016/j.patol.2018.02.004.

    PMID: 30583835
  2. 2

    Review of the medical literature and assessment of current utilization patterns regarding the use of two common fluorescence in situ hybridization assays in the diagnosis of dermatofibrosarcoma protuberans and clear cell sarcoma.

    Linos K, Kozel JA, Hurley MY, Andea AA

    Journal of cutaneous pathology 2018; (45(12)):905-913 doi:10.1111/cup.13345.

    PMID: 30155908
  3. 3

    Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas.

    Koseła-Paterczyk H, Rutkowski P

    Expert review of anticancer therapy 2017; (17(12)):1107-1116 doi:10.1080/14737140.2017.1390431.

    PMID: 28988501
  4. 4

    A Novel Chromosomal Translocation Associated With COL1A2-PDGFB Gene Fusion in Dermatofibrosarcoma Protuberans: PDGF Expression as a New Diagnostic Tool.

    Nakamura I, Kariya Y, Okada E, et al.

    JAMA dermatology 2015; (151(12)):1330-1337 doi:10.1001/jamadermatol.2015.2389.

    PMID: 26332510
  5. 5

    Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusions.

    Dadone-Montaudié B, Alberti L, Duc A, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2018; (31(11)):1683-1693 doi:10.1038/s41379-018-0089-4.

    PMID: 29955147
  6. 6

    COL1A1::PDGFB fusion-associated uterine fibrosarcoma: A case report and review of the literature.

    Rota S, Franza A, Fabbroni C, et al.

    Cancer reports (Hoboken, N.J.) 2024; (7(2)):e1969 doi:10.1002/cnr2.1969.

    PMID: 38279510
  7. 7

    Dermatofibrosarcoma Protuberans Of Trunk In A Male Patient.

    Hashmi JZ, Ghafoor A, Rauf Khan Hiraj MU, Chaudhary WA

    Journal of Ayub Medical College, Abbottabad : JAMC 2022; (34(2)):364-365 doi:10.55519/JAMC-02-8960.

    PMID: 35576304
  8. 8

    Review of dermatofibrosarcoma protuberans.

    Lim SX, Ramaiya A, Levell NJ, Venables ZC

    Clinical and experimental dermatology 2023; (48(4)):297-302 doi:10.1093/ced/llac111.

    PMID: 36630365
  9. 9

    Dermatofibrosarcoma protuberans with fibrosarcomatous transformation: A tale of unbridled expansion.

    Reid AT, Berger A, Johnson-Jahangir H

    JAAD case reports 2020; (6(10)):1006-1008 doi:10.1016/j.jdcr.2020.07.053.

    PMID: 32995431
  10. 10

    A case of aggressive giant dermatofibrosarcoma protuberance occurring in the parotid gland.

    Adilbay D, Khozhamkul F, Toiynbekova S, Ahmetov D

    International journal of surgery case reports 2019; (55()):58-61 doi:10.1016/j.ijscr.2018.12.006.

    PMID: 30703718
  11. 11

    Immunohistochemical Profiles of Dermatofibroma and Dermatofibrosarcoma Protuberans: A Scoping Review.

    Hardy CSC, Razavi A, Nunez N, et al.

    Applied immunohistochemistry & molecular morphology : AIMM 2026; (34(1)):5-14 doi:10.1097/PAI.0000000000001284.

    PMID: 41145392
  12. 12

    Targeted therapy and immunotherapy for orbital and periorbital tumors: a major review.

    Lee Boniao E, Allen RC, Sundar G

    Orbit (Amsterdam, Netherlands) 2024; (43(5)):656-673 doi:10.1080/01676830.2023.2256848.

    PMID: 37728602
  13. 13

    Dermatofibrosarcoma Protuberans in Children.

    Sleiwah A, Wright TC, Chapman T, et al.

    Current treatment options in oncology 2022; (23(6)):843-854 doi:10.1007/s11864-022-00979-9.

    PMID: 35394606
  14. 14

    Dermatofibrosarcoma Protuberans Re-excision and Recurrence Rates in the Netherlands Between 1989 and 2016.

    van Lee CB, Kan WC, Gran S, et al.

    Acta dermato-venereologica 2019; (99(12)):1160-1165 doi:10.2340/00015555-3287.

    PMID: 31410492
  15. 15

    Dermatofibrosarcoma Protuberans: An Updated Review of the Literature.

    Jozwik M, Bednarczuk K, Osierda Z

    Cancers 2024; (16(18)) doi:10.3390/cancers16183124.

    PMID: 39335097
  16. 16

    Dermatofibrosarcoma Protuberans: A Study of 148 Patients.

    Marcoval J, Moreno-Vílchez C, Torrecilla-Vall-Llosera C, et al.

    Dermatology (Basel, Switzerland) 2024; (240(3)):487-493 doi:10.1159/000536172.

    PMID: 38228098
  17. 17

    Determination of COL1A1-PDGFB breakpoints by next-generation sequencing in the molecular diagnosis of dermatofibrosarcoma protuberans.

    Zhu R, Yan J, Li B, et al.

    Experimental and molecular pathology 2021; (122()):104672 doi:10.1016/j.yexmp.2021.104672.

    PMID: 34371012

This page explains DFSP pathology and genetics for educational purposes only. Always review your specific pathology report and diagnosis with your oncologist or sarcoma specialist.

Get notified when new evidence is published on Dermatofibrosarcoma protuberans.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.